Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
I am looking for
added new label for I am looking for
Advanced Filters
Found 492 clinical trials
Featured trial
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099280 in Participants With Advanced Solid Tumors

The purpose of this study is to evaluate the safety and tolerability, pharmacokinetics, pharmacodynamics, and early clinical activity of INCB099280 in participants with select solid tumors

  • 19 Jun, 2022
  • 16 locations
  • 07 Jan, 2022
  • 18 locations
A Study of HMPL-295S1 in Patients With Advanced Malignant Solid Tumors

The objective of this study is to evaluate the safety, tolerability and PK profile of HMPL-295S1 and determine MTD and/or RP2D in patients with advanced malignant solid tumor. It will be

  • 11 Sep, 2021
  • 1 location
Assessment of Safety and Preliminary Clinical Efficacy With BAT6005 in Advanced Malignant Solid Tumors

malignant solid tumors in the safety, tolerability and PK characteristics, to explore the maximum tolerated dose and preliminary antitumor efficacy, provide the basis for subsequent clinical trials

  • 14 Dec, 2021
  • 1 location
Genakumab Alone and in Combination With Tislelizumab in Patients With Advanced Malignant Solid Tumors

This is a phase I, multicenter, open-label dose escalation and expansion study to evaluate genakumab alone and in combination with tislelizumab in adult patients with advanced solid malignancies.

  • 28 Jul, 2022
  • 1 location
Phase I Clinical Trial of TQB3915 Tablets in Subjects With Advanced Malignant Solid Tumors

TQB3915 is a selective estrogen receptor covalent antagonist, by covalently binding to estrogen receptor, by changing the conformation of ERα, blocking intracellular signal transmission, thereby inhibiting the growth of tumor cells.

  • 29 Jun, 2022
  • 3 locations
A Phase Ⅰa Clinical Study Exploring Efficacy of SIBP-03 When Treating the Patients With Advanced Malignant Solid Tumors.

The main purpose of • To evaluate the safety, tolerability and pharmacokinetic characteristics of SIBP-03(Recombinant anti-HER3 humanized monoclonal antibody injection). A secondary purpose Assess the immunogenicity of SIBP-03. Exploratory purpose Explore potential biomarkers; Preliminary evaluation of the antitumor efficacy of SIBP-03.

breast cancer
targeted therapy
primary cancer
blood transfusion
  • 24 Mar, 2022
  • 1 location
A Phase I Clinical Study of Recombinant Humanized Monoclonal Antibody MIL95 Injection in the Treatment of Lymphomas and Advanced Malignant Solid Tumors

This study is composed of two stages: Part A initial dose escalation and Part B maintenance dose escalation. Both parts will adopt the classical 3+3 dose escalation design. The starting dose for phase Ia part A is 0.1 mg/kg QW, followed by 3 dose cohorts (0.3mg/kg QW, 0.8mg/kg QW and …

  • 17 Sep, 2022
  • 1 location
First-in-Human, Open-label, Dose-Escalation Trial With an Expansion Cohort to Evaluate the Safety of GEN1053 as Monotherapy in Subjects With Malignant Solid Tumors

The drug that will be investigated in the study is GEN1053. GEN1053 is an antibody designed to (re)activate and increase antitumor immunity. Since this is the first study of GEN1053 in humans, the main purpose is to evaluate safety. Besides safety, the study will determine the recommended GEN1053 dose to …

  • 14 Sep, 2022
An Open-label, Multicenter, Multicohort, Phase 2 Study to Evaluate Enfortumab Vedotin in Subjects With Previously Treated Locally Advanced or Metastatic Malignant Solid Tumors (EV-202)

The primary purpose of this study is to determine the antitumor activity of enfortumab vedotin as measured by confirmed objective response rate (ORR). This study will also assess other measures of antitumor activity; overall survival (OS); as well as the safety and tolerability of enfortumab vedotin.

  • 23 Sep, 2022
  • 46 locations